Other equities analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of Protalix Biotherapeutics from a sell rating to a hold rating in a report on Wednesday, January 10th. BidaskClub lowered shares of Protalix Biotherapeutics from a sell rating to a strong sell rating in a report on Saturday, December 2nd.
Protalix Biotherapeutics (NYSEAMERICAN PLX) opened at $0.69 on Wednesday. The firm has a market cap of $329.82, a price-to-earnings ratio of -0.34 and a beta of 0.97. Protalix Biotherapeutics has a 1-year low of $0.48 and a 1-year high of $1.51.
An institutional investor recently bought a new position in Protalix Biotherapeutics stock. Opaleye Management Inc. bought a new position in Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,825,000 shares of the company’s stock, valued at approximately $1,206,000. Opaleye Management Inc. owned about 1.27% of Protalix Biotherapeutics as of its most recent filing with the Securities and Exchange Commission.
Protalix Biotherapeutics Company Profile
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease.
Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.